Skip to main content

MAKING ANTIBODIES IN BULK: 
AT WHAT COST?

The HIV vaccine field is still in the midst of an antibody renaissance. Following the isolation of a handful of more broad and potent neutralizing antibodies five years ago, researchers have been busily studying these antibodies, identifying their targets on the virus, and using this information to advance the arduous task of designing vaccine immunogens capable of insuring such antibodies.


Meanwhile, these antibodies are also being pursued in other avenues of HIV prevention and treatment research. Should any of these efforts prove successful, the need to manufacture HIV monoclonal antibodies on an industrial scale may be necessary. But making these antibodies isn't cheap. Find out what is being done to improve antibody manufacturing and lower costs now, as well as what research was highlighted at the recent meeting of the HIV Vaccine Trials Network. Plus, a look at the staggering HIV rates among young, black men who have sex with men in the US. Read more...

 
SPECIAL UPDATE

We extend our sincere condolences to the friends, family and colleagues who have been affected by the Malaysian Airlines tragedy. Please click here for a statement from the International AIDS Society.

 

LATEST BLOG POSTS

Keystone meeting in Rio: Breakthroughs and surprises

READ MORE
B cells wage a losing battle against HIV

READ MORE
Are HIV reservoirs larger than previously suspected?

READ MORE
A new mechanism for HIV control?

READ MORE

Recent Features

Living Positive in Malaysia

Q&A with Andrew Tan, founder and president of myPlus, a network of HIV-positive people in Malaysia. Tan came out in public as an HIV-positive gay man in his speech opening night of IAS 2013.

READ MORE

Clinical Trials Database

image description Explore

An interactive search of trials and results

READ MORE

Upcoming Meetings

16th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV October 06 - 08, 2014 Philadelphia, PA
3rd Antivirals Congress October 12 - 14, 2014 Amsterdam, The Netherlands
5th International Conference on Retroviral Integration October 23 - 26, 2014 Pacific Grove, CA
view all

Not a Scientist?

cover art url

VAX is the bulletin on AIDS vaccine research for you.

AIDS 2014: Much Accomplished, Much More to Achieve

Despite tremendous gains in the realms of HIV treatment and prevention, the focus at AIDS 2014 was on what still needs to be done.

READ MORE

DOWNLOAD PDF